Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet medical needs. The company's core business revolves around its FDA-approved oral therapy, LUPKYNIS (voclosporin), for active lupus nephritis (LN), and the development of aritinercept, a dual inhibitor for other autoimmune diseases. Aurinia generates revenue primarily through direct sales of LUPKYNIS in the U.S. to two specialty pharmacies and a specialty distributor, and through its collaboration with Otsuka Pharmaceutical Co., Ltd. for sales in European and Japanese markets. This collaboration includes supplying LUPKYNIS inventory to Otsuka at cost plus a margin, and providing manufacturing and other services, including sharing capacity of a dedicated manufacturing facility.

LUPKYNIS (voclosporin) is the first FDA-approved oral therapy for adult patients with active LN, a severe complication of systemic lupus erythematosus (SLE). An estimated 20% to 60% of over 200,000 SLE patients in the U.S. develop LN. LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) immunosuppressant, indicated in combination with background immunosuppressive therapy. Its FDA approval was based on the pivotal Phase 3 AURORA 1 study, which showed a significantly higher complete renal response (CRR) at week 52 (40.8% vs. 22.5%; p<0.001) and week 24 (32.4% vs. 19.7%; p=0.002) when LUPKYNIS was added to mycophenolate mofetil (MMF) and corticosteroids. New post-hoc analyses in 2025, using data from AURORA 1, AURORA 2, and AURA-LV studies, further support LUPKYNIS's robust clinical benefit, demonstrating a statistically significant reduction in the risk of Renal-Related Events or Death.

Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), being developed for autoimmune diseases. It features a B cell maturation antigen (BCMA)-engineered extracellular binding domain for superior affinity to BAFF and APRIL, and an immunoglobulin (Ig) G4 fragment crystallizable (Fc) domain with no appreciable effector function, making it less inflammatory. Aritinercept aims to deplete a broader set of B cells, including plasma cells, and reduce autoreactive B cells and associated immunoglobulins. Initial clinical studies (SAD study) in 61 healthy subjects showed aritinercept was well tolerated across all tested doses (5 mg, 25 mg, 75 mg, 150 mg, 225 mg, and 300 mg), with no treatment-related Grade ≥3 adverse events or serious adverse events. Single doses led to robust and long-lasting reductions in immunoglobulins, with mean reductions from baseline to Day 28 of up to 48% for IgA, 55% for IgM, and 20% for IgG, supporting once-monthly dosing.

For the fiscal year ended December 31, 2025, Aurinia reported total revenue of $283.055 million ¹, an increase from $235.133 million ² in 2024. Net product sales were $271.345 million ³, up 25% from $216.186 million ⁴ in 2024. License, collaboration, and royalty revenue decreased to $11.710 million ⁵ from $18.947 million ⁶ in 2024. Cost of revenue was $32.665 million ⁷, resulting in a gross margin of 88% ⁸ for both 2025 and 2024. Operating expenses totaled $178.141 million ⁹, down from $239.820 million ¹⁰ in 2024. Income from operations was $104.914 million ¹¹, a significant improvement from a loss of $4.687 million ¹² in 2024. Net income before income taxes was $114.157 million ¹³, compared to $7.448 million ¹⁴ in 2024. The company recorded an income tax benefit of $173.045 million ¹⁵, leading to a net income of $287.202 million ¹⁶ for 2025, up from $5.752 million ¹⁷ in 2024. Basic EPS was $2.14 ¹⁸ and diluted EPS was $2.07 ¹⁹. Cash flows from operating activities were $135.658 million ²⁰, a 206% increase from $44.388 million ²¹ in 2024. As of December 31, 2025, cash, cash equivalents, restricted cash, and investments stood at $398.0 million ²², compared to $358.5 million ²³ at December 31, 2024. Total liabilities were $170.256 million ²⁴ and total shareholders' equity was $581.331 million ²⁵.

The year-over-year increase in net product sales of $55.159 million ²⁶ was primarily driven by an increase in LUPKYNIS cartons sold to specialty pharmacies, indicating further LN market penetration. License, collaboration, and royalty revenue decreased by $7.237 million ²⁷ due to a $10.0 million ²⁸ milestone payment in 2024 associated with LUPKYNIS regulatory approval in Japan, which did not recur in 2025. Cost of revenue increased by $4.417 million ²⁹ due to higher net product sales. Selling, general and administrative (SG&A) expense decreased significantly by $70.234 million ³⁰ to $101.794 million ³¹, primarily due to lower employee-related costs, including share-based compensation, and reduced marketing, professional fees, and other overhead resulting from strategic restructuring efforts in 2024. Research and development (R&D) expense increased by $11.720 million ³² to $32.505 million ³³, mainly due to higher employee-related costs and increased clinical supply and distribution costs for development activities. Restructuring expense decreased substantially to $1.647 million ³⁴ in 2025 from $23.106 million ³⁵ in 2024, reflecting the completion of the strategic restructuring efforts. The income tax benefit of $173.045 million ³⁶ in 2025 was primarily due to the release of the valuation allowance on deferred tax assets, which the company now expects to realize.

During 2025, Aurinia conducted new LUPKYNIS data analyses supporting its clinical benefit, reinforcing efficacy and safety. The company also initiated a clinical study of aritinercept in one autoimmune disease and plans to initiate another in the first half of 2026. In February and March 2025, Aurinia received paragraph IV notice letters from eight generic companies seeking to market generic versions of LUPKYNIS, leading Aurinia to file patent infringement complaints. The company repurchased 12.2 million ³⁷ common shares for $98.2 million ³⁸ in 2025, as part of an expanded share repurchase plan, which was increased by an additional $150 million ³⁹ on July 31, 2025.

Aurinia expects its selling, general and administrative (SG&A) expense in 2026 to remain substantially consistent with 2025 levels. Research and development (R&D) expense is projected to continue increasing as the company progresses its development activities.

A key growth area for Aurinia is the continued commercialization of LUPKYNIS, particularly through further market penetration in the LN market. The company also anticipates growth from its collaboration with Otsuka Pharmaceutical Co., Ltd., which markets LUPKYNIS in Japan, the E.U., the U.K., and Switzerland, with Otsuka having already obtained regulatory approval in these territories. The commercial supply agreement with Otsuka, which involves supplying LUPKYNIS inventory at cost plus a margin and sharing manufacturing capacity, is expected to contribute to future revenue.

Another significant growth vector is the development of aritinercept, a dual inhibitor of BAFF and APRIL for autoimmune diseases. Aurinia has initiated a clinical study of aritinercept in one autoimmune disease and plans to initiate a clinical study in an additional autoimmune disease in the first half of 2026. The initial single ascending dose (SAD) study of aritinercept demonstrated robust and long-lasting reductions in immunoglobulins, supporting once-monthly dosing, which could be a competitive advantage if approved.

Operationally, the company's strategic restructuring efforts in 2024, which included a 25% headcount reduction in February 2024 and a further 45% reduction in November 2024, are expected to contribute to cost management, particularly in SG&A expenses, which are projected to remain consistent in 2026 compared to 2025. The company's manufacturing and supply chain strategy relies on third-party manufacturers, with Lonza as the sole supplier for voclosporin drug substance and Catalent Pharma Solutions as the sole supplier for encapsulation. The dedicated Monoplant facility, for which Aurinia pays a quarterly fixed facility fee of 3.6 million Swiss Francs ⁴⁰ through March 31, 2030 ⁴¹, is equipped to provide cost and production efficiency, expand capacity, and ensure supply security for future commercial demand. Aurinia believes it has enough inventory and manufacturing capacity to meet forecasted demand.

Regarding capital allocation, Aurinia's Board approved a share repurchase program of up to $150 million ⁴² in February 2024, which was increased by an additional $150 million ⁴³ on July 31, 2025. As of December 31, 2025, the company had repurchased 18.3 million ⁴⁴ common shares for $138.6 million ⁴⁵ under this plan. The timing and amount of future repurchases will be determined based on market conditions, share price, and legal requirements. The company has never paid dividends on its common shares and has no plans to do so. Based on current operating plans and projections, Aurinia expects to fund future operations with existing cash or cash flows from operating activities.

Management has explicitly flagged several structural headwinds and execution risks. The commercial success of LUPKYNIS is substantially dependent on the company's ability to maintain an effective sales and marketing organization, and its ability to further change treatment practices, given competition from BENLYSTA, GAZYVA, and off-label use of MMF and corticosteroids or first-generation CNIs. Estimates of the potential market size for LUPKYNIS are based on various data, and if the actual market is smaller, commercial prospects could be limited. The commercial success of LUPKYNIS in ex-U.S. territories is also dependent on Otsuka's ability to successfully commercialize the product and Aurinia's fulfillment of commercial supply obligations. Furthermore, unfavorable pricing regulations and third-party coverage and reimbursement policies, including those stemming from the Inflation Reduction Act of 2022, could limit LUPKYNIS's commercial prospects. The company is also subject to various federal, state, and foreign laws and regulations governing the healthcare industry, including anti-kickback statutes and false claims laws, with noncompliance potentially leading to substantial penalties.

Aurinia faces material risks related to the commercialization of LUPKYNIS, including intense competition from FDA-approved injectable treatments like BENLYSTA and GAZYVA, as well as off-label use of MMF and corticosteroids or first-generation CNIs, which could limit sales growth. Product liability lawsuits are a significant concern due to the serious nature of LN and potential adverse events associated with LUPKYNIS, which could lead to substantial liabilities and reduced sales, despite product liability insurance. The commercial success of LUPKYNIS in ex-U.S. territories is contingent on the collaboration with Otsuka, and any failure by either party to meet contractual obligations could adversely affect business. Pricing regulations and third-party reimbursement policies, particularly those influenced by the Inflation Reduction Act of 2022, pose a risk to market acceptance and net product sales. Noncompliance with healthcare fraud and abuse laws, such as the federal Anti-Kickback Statute and False Claims Act, could result in substantial penalties, including civil and criminal fines. Intellectual property risks are high, with eight generic companies having filed ANDAs challenging LUPKYNIS's 2037 Patents, leading to ongoing patent infringement litigation that is expected to incur significant costs and could result in a decline in LUPKYNIS net product sales if generic versions are approved. The company's reliance on sole-source contract manufacturers for LUPKYNIS drug substance and encapsulation creates supply chain vulnerability, where any interruption could adversely impact the business. Drug development for aritinercept is lengthy, expensive, and uncertain, with no guarantee that clinical studies will demonstrate sufficient safety and efficacy for regulatory approval, or that earlier study results will be predictive of future outcomes. Geopolitical actions, natural disasters, or public health crises could cause business interruptions, particularly affecting the supply chain. As an Alberta, Canada corporation with some officers residing outside the U.S., there is a risk that U.S. laws and judgments may not be enforceable against the company or its officers. Cybersecurity threats, including computer system failures or security breaches, could lead to loss of data, trade secrets, or confidential information, resulting in liability and delays in product development. The Canada Income Tax Act includes an excise tax on share repurchases, which will increase the cost of share repurchases.

Management's message to shareholders emphasizes a sharpened focus on continued LUPKYNIS growth and the development of aritinercept, following strategic restructuring efforts in 2024 that reduced headcount by approximately 25% and then a further 45%. They highlight the robust clinical benefit of LUPKYNIS, supported by new data analyses in 2025, and the promising initial clinical study results for aritinercept, which showed it was well tolerated and led to robust, long-lasting reductions in immunoglobulins, supporting once-monthly dosing. Management intends to vigorously enforce its intellectual property rights related to LUPKYNIS, particularly in response to the paragraph IV notice letters received from generic companies in February and March 2025. The company expects its SG&A expense in 2026 to remain substantially consistent with 2025, while R&D expense is projected to continue increasing as development activities progress. Aurinia's Board has demonstrated a commitment to returning capital to shareholders, as evidenced by the increase in the share repurchase plan by an additional $150 million ⁴⁶ on July 31, 2025, bringing the total authorized amount to $300 million ⁴⁷.